| Drug Name |
Emtricitabine |
| Drug ID |
BADD_D00766 |
| Description |
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults[L9019] or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and adults.[L9010] Emtricitabine is a cytidine analogue.[L9019] The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.[L9019]
Emtricitabine was granted FDA approval on 2 July 2003.[L9019] |
| Indications and Usage |
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections;[L9019,L9836] treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex;[L4388,L9010] treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg;[L9833] treatment of HIV-1 in patients ≥12 years and ≥35kg;[L9587] treatment of HIV-1 in patients weighing ≥35kg;[L9839,L9842] treatment of HIV-1 in patients weighing ≥25kg;[L9647,L9845] and treatment of HIV-1 in patients weighing ≥40kg.[L9848] |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AF09 |
| DrugBank ID |
DB00879
|
| KEGG ID |
D01199
|
| MeSH ID |
D000068679
|
| PubChem ID |
60877
|
| TTD Drug ID |
D0S9SD
|
| NDC Product Code |
65015-827; 65862-301; 61958-0601; 70966-0024; 70518-2906; 33342-500; 42385-710; 53104-7637; 65862-305; 65015-883; 72761-008; 49711-1516; 68554-0064; 69037-0003; 69097-642; 65015-838; 61958-0602; 68554-0027; 52696-0008; 59997-0005; 42385-304; 66406-0209; 66721-400 |
| UNII |
G70B4ETF4S
|
| Synonyms |
Emtricitabine | Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine | Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine | Coviracil | Emtriva |
